| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Deubiquitinating enzyme 10; UBPO; USP10 |
| Entrez GeneID | 9100 |
| WB Predicted band size | Calculated MW: 87 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human USP10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于USP10抗体的参考文献示例(注：文献为虚构示例，仅供参考格式)：
1. **《USP10 regulates p53 stability by deubiquitinating and stabilizing p53 in response to DNA damage》**
*作者：Yuan J. et al.*
摘要：本研究通过使用USP10特异性抗体，证实USP10在DNA损伤后通过去泛素化作用稳定p53蛋白，促进细胞凋亡，揭示了其在肿瘤抑制中的关键机制。
2. **《The dual role of USP10 in cancer progression and therapy resistance》**
*作者：Sacco M. et al.*
摘要：文章利用USP10抗体进行免疫共沉淀实验，发现USP10通过调控多种底物(如PTEN和c-Myc)的稳定性，在癌症中发挥促存活或促凋亡的双重作用，与化疗敏感性相关。
3. **《USP10 modulates TDP-43 aggregation and autophagy in neurodegenerative disease models》**
*作者：Liu X. et al.*
摘要：通过抑制USP10抗体功能，研究发现USP10参与清除TDP-43蛋白聚集，并调控自噬通路，为阿尔茨海默病等神经退行性病变提供了潜在治疗靶点。
4. **《Development of a monoclonal antibody targeting USP10 for therapeutic inhibition in hepatocellular carcinoma》**
*作者：Hussain S. et al.*
摘要：研究团队开发了一种高特异性USP10单克隆抗体，证实其可通过阻断USP10与底物的相互作用抑制肝癌细胞增殖，并增强索拉非尼的化疗效果。
The ubiquitin-specific protease 10 (USP10) is a member of the deubiquitinating enzyme (DUB) family, which regulates protein stability, localization, and interactions by removing ubiquitin chains from substrate proteins. USP10 plays critical roles in diverse cellular processes, including stress response, DNA repair, cell cycle regulation, and tumorigenesis. Key substrates of USP10 include p53. CFTR, and AMPK, highlighting its involvement in modulating cell fate decisions, protein trafficking, and metabolic pathways. Dysregulation of USP10 has been implicated in diseases such as cancer, cystic fibrosis, and neurodegenerative disorders.
USP10 antibodies are essential tools for studying its expression, subcellular localization, and interaction partners. Research shows USP10's dual role in cancer—acting as a tumor suppressor by stabilizing p53 to promote apoptosis or as an oncogene by deubiquitinating and stabilizing oncoproteins like Notch1. Its cytoplasmic-nuclear shuttling under stress conditions further underscores its context-dependent functions. In cystic fibrosis, USP10 regulates the CFTR chloride channel, influencing its trafficking and activity.
Antibodies targeting USP10 enable investigations into its regulatory mechanisms, post-translational modifications, and therapeutic potential. However, conflicting findings in different cancer models emphasize the need for precise experimental validation using specific antibodies to avoid off-target effects. Overall, USP10 remains a compelling research target due to its multifaceted roles in health and disease.
×
